End of stabilization period
Nov 3, 2020
With reference to company announcement no. 56/2020 dated September 29, 2020 regarding beginning of the stabilization period following the global offering (the “Global Offering”), consisting of an initial public offering of American Depositary Shares (the “ADSs”), each such ADS representing one ordinary share of Orphazyme, in the United States (the "U.S. Offering"), and a concurrent private placement of ordinary shares in Europe traded on Nasdaq Copenhagen A/S under the symbol “ORPHA” (the “European Private Placement”), Orphazyme A/S ("Orphazyme") has received notification that BofA Securities, Inc., who is acting as stabilizing manager in the Global Offering, that the stabilization period has ended and that (i) stabilization measures have been taken between September 29, 2020 and October 28, 2020 as set out in the attached end of stabilization notification from BofA Securities, Inc., given on its and its affiliate, BofA Securities Europe SA, behalf to Orphazyme, with respect to the ADSs admitted to trading on the Nasdaq Global Select Market in the United States under the symbol “ORPH”; (ii) no stabilization transactions have been taken in the ordinary shares of Orphazyme admitted to trading on Nasdaq Copenhagen A/S during the stabilization period; and (iii) the stabilization measures with respect to the ADSs set out in the attached mid-stabilization notification have been taken.
Read moreStabilization measures taken
Oct 27, 2020
With reference to company announcement no. 56/2020 dated September 29, 2020 regarding beginning of the stabilization period following the global offering (the “Global Offering”), consisting of an initial public offering of American Depositary Shares (the “ADSs”), each such ADS representing one ordinary share (the “Ordinary Shares”), in the United States (the "U.S. Offering"), and a concurrent private placement of Ordinary Shares in Europe (the “European Private Placement”), Orphazyme A/S ("Orphazyme") has received notification from BofA Securities, Inc., who is acting as stabilizing manager in the Global Offering, that the stabilization measures set out in the attached notification have been taken. Reference is made to the attached notification from BofA Securities, Inc., given on its and its affiliate, BofA Securities Europe SA, behalf to Orphazyme, with respect to the ADSs of Orphazyme traded on the Nasdaq Global Select Market in the United States and the Ordinary Shares of Orphazyme traded on Nasdaq Copenhagen A/S, respectively.
Attachments notification from bofa securities inc
Read moreOrphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020
Oct 23, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein (HSP) response for the treatment of neurodegenerative orphan diseases, today announces an update to its financial outlook for 2020. The update is primarily driven by an acceleration in commercial and other pre-launch activities during the fourth quarter of 2020 in preparation for potential approval of its investigational product candidate arimoclomol in Niemann-Pick disease Type C (NPC), which is currently under Priority Review by the U.S. Food and Drug Administration (FDA) with a target action date of March 17, 2021.
Orphazyme accelerates arimoclomol
Read moreStabilization measures taken
Oct 16, 2020
With reference to company announcement no. 56/2020 dated September 29, 2020 regarding beginning of the stabilization period following the global offering (the “Global Offering”), consisting of an initial public offering of American Depositary Shares (the “ADSs”), each such ADS representing one ordinary share (the “Ordinary Shares”), in the United States (the "U.S. Offering"), and a concurrent private placement of Ordinary Shares in Europe (the “European Private Placement”), Orphazyme A/S ("Orphazyme") has received notification from BofA Securities, Inc., who is acting as stabilizing manager in the Global Offering, that the stabilization measures set out in the attached notification have been taken. Reference is made to the attached notification from BofA Securities, Inc., given on its and its affiliate, BofA Securities Europe SA, behalf to Orphazyme, with respect to the ADSs of Orphazyme traded on the Nasdaq Global Select Market in the United States and the Ordinary Shares of Orphazyme traded on Nasdaq Copenhagen A/S, respectively.
Attachments notification from bofa securities inc v2
Read moreMajor shareholder announcement
Oct 9, 2020
Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that as of October 8, 2020, Danske Bank A/S holds a total of 1,346,609 shares in Orphazyme, corresponding to 3.88% of the share capital and that Danske Bank A/S as of October 8, 2020 controls 5.47% of the voting rights in Orphazyme.
Major shareholder announcement
Read moreStabilization measures taken
Oct 8, 2020
With reference to company announcement no. 56/2020 dated September 29, 2020 regarding beginning of the stabilization period following the global offering (the “Global Offering”), consisting of an initial public offering of American Depositary Shares (the “ADSs”), each such ADS representing one ordinary share (the “Ordinary Shares”), in the United States (the "U.S. Offering"), and a concurrent private placement of Ordinary Shares in Europe (the “European Private Placement”), Orphazyme A/S ("Orphazyme") has received notification from BofA Securities, Inc., who is acting as stabilizing manager in the Global Offering, that the stabilization measures set out in the attached notification have been taken. Reference is made to the attached notification from BofA Securities, Inc., given on its and its affiliate, BofA Securities Europe SA, behalf to Orphazyme, with respect to the ADSs of Orphazyme traded on the Nasdaq Global Select Market in the United States and the Ordinary Shares of Orphazyme traded on Nasdaq Copenhagen A/S, respectively.
Read moreMajor shareholder announcement
Oct 5, 2020
Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that as of October 2, 2020, Danske Bank A/S holds a total of 1,148,770 shares in Orphazyme, corresponding to 3.31% of the share capital and that Danske Bank A/S as of October 2, 2020 controls 4.91% of the voting rights in the Orphazyme.
Major shareholder announcement
Read moreMajor shareholder announcement
Oct 5, 2020
Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Consonance Capman GP LLC that as of October 1, 2020, Consonance Capman GP LLC has reduced its indirect holdings of shares and voting rights in Orphazyme and now indirectly holds 1,339,909 shares and voting rights in Orphazyme, corresponding to 3.86% of the total share capital and voting rights of Orphazyme.
Major shareholder announcement
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Oct 2, 2020
Orphazyme A/S (ORPHA; ORPH) (“Orphazyme”), CVR no. 32266355, a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, pursuant to the Market Abuse Regulation article 19, hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme or their closely associated persons.
Reporting of transactions in orphazymes shares made
Read moreMajor shareholder announcement
Oct 1, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby notifies receipt of the attached major shareholder notification pursuant to Section 30 of the Danish Capital Markets Act.
Major shareholder announcement
Read more